• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [916 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2026 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2026 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Newborn screening for metachromatic leukodystrophy]
2026 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the lower age limit and frequency of early-detection colonoscopy in the colorectal cancer screening programme]
2026 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risk-adapted PSA and MRI screening for early detection of prostate cancer]
2026 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, clinical effectiveness and cost-effectiveness of neonatal screening for Pompe disease]
2026 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, clinical and cost-effectiveness of neonatal screening for type 1 citrullinaemia, trifunctional protein deficiency, holocarboxyl synthetase deficiency, argininosuccinic aciduria and 3-methylcrotonyl-CoA carboxylase deficiency]
2026 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety, clinical effectiveness, and cost-effectiveness of neonatal screening for beta-ketothiolase deficiency and classic galactosemia. Update]
2026 NIHR Health Technology Assessment programme Methods and mechanisms for measuring and monitoring outcomes from newborn bloodspot screening: a scoping review
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of colorectal cancer in people with a family risk]
2025 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of extending population-based breast cancer screening to women aged 45–49 and 70–74 and the use of digital breast tomosynthesis in screening women with dense breast tissue]
2025 NIHR Health Technology Assessment programme Multi-cancer early detection tests for general population screening: a systematic literature review
2025 Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for mucopolysaccharidosis Type II (MPS II; Hunter syndrome)
2025 Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)
2025 Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for glycogen storage disease, Type II (GSD II; Pompe disease)
2025 Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of adding vitamin-dependent rickets screening to neonatal screening]
2025 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Newborn screening for Metachromatic leukodystrophy (MLD)]
2025 NIHR Health Technology Assessment programme Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviews
2025 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of genetic tests related to hearing loss and their role in neonatal population screening]
2025 Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of the use of HIV rapid test kits by community workers in Québec]
2025 NIHR Health Technology Assessment programme The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks
2025 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) Monitoring study protocol: left ventricular assist devices destination therapy
2025 NIHR Health Technology Assessment programme Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral in primary care. A systematic review, meta-analysis and cost-effectiveness analysis
2025 Institut national d'excellence en sante et en services sociaux (INESSS) [Access to breast cancer screening for Québec women aged 40 to 49: issues, considerations and implementation approach]
2025 Austrian Institute for Health Technology Assessment (AIHTA) Further development of the program on preventive health check-ups: screening for chronic kidney disease – a rapid review of benefits, harms and target populations
2025 Austrian Institute for Health Technology Assessment (AIHTA) Further development of the programme on preventive medical check-ups in Austria. Risk scores for cardiovascular disease: a systematic review
2025 The Regional Health Technology Assessment Centre (HTA-centrum) Cervical length screening followed by progesterone with or without additional treatment for short cervix to prevent preterm birth
2025 Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of adding screening for vitamin D-dependent rickets to the Quebec Neonatal Blood Screening Program]
2025 Health Information and Quality Authority (HIQA) Draft health technology assessment of extending BowelScreen to those aged 50 to 54 years
2025 HTA South [Screening for diabetic retinopathy with artificial intelligence for image analysis: a systematic review and assessment of medical, economical, ethical and organisational aspects]
2025 Belgian Health Care Knowledge Centre (KCE) Update of breast cancer screening recommendations (Study 2024-11)
2025 Belgian Health Care Knowledge Centre (KCE) Update of prostate cancer screening recommendations (Study 2024-10)
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on lung cancer screening using low-dose computed tomography]
2025 National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment. NICE HealthTech guidance 760
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: evaluation of the lung cancer screening pilot project - effects on participants' health and organizational impact on the healthcare system]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for the early detection of familial hypercholesterolaemia in children and adolescents]
2024 Health Information and Quality Authority (HIQA) Evidence review of universal ultrasound screening for developmental dysplasia of the hip (DDH) in infants in Ireland
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of lung cancer screening using low-dose computed tomography]
2024 Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of screening for abdominal aortic aneurysm in men
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Multi-stage evaluation and revision of information materials on the mammography screening programme]
2024 NIHR Health Technology Assessment programme Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation
2024 Canary Health Service [Cost-effectiveness of neonatal screening for spinal muscular atrophy and severe combined immunodeficiency]
2024 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism by MS/MS. Update: Carnitine uptake deficiency; very long chain acyl-CoA dehydrogenase deficiency]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: equivalence of the positivity threshold of immunochemical fecal occult blood tests for colorectal cancer screening]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: screening for cancers, chronic diseases and STBBIs]
2024 Belgian Health Care Knowledge Centre (KCE) Lung cancer screening in a high-risk population
2024 Malaysian Health Technology Assessment (MaHTAS) Whole exome sequencing for children with suspected genetic disease
2024 Malaysian Health Technology Assessment (MaHTAS) Wide field digital eye imaging system for universal neonatal eye screening
2024 Malaysian Health Technology Assessment (MaHTAS) Podoscope for footprint analysis
2024 Malaysian Health Technology Assessment (MaHTAS) Breath test for tuberculosis
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: breast cancer screening with breast tomosynthesis]
2024 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, efficacy, effectiveness, and efficiency of systematic neonatal screening for the detection of congenital cytomegalovirus]
2024 Malaysian Health Technology Assessment (MaHTAS) Handheld fundus camera - an update
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early screening in pregnant women with risk factors: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding universal screening for congenital cytomegalovirus (CMV) infection to Québec newborn screening program]
2024 Institute of Health Economics (IHE) Mammography screening for breast cancer: a replication of a systematic review of observational studies to inform an update of the Canadian Task Force on Preventive Health Care guidelines
2024 Austrian Institute for Health Technology Assessment (AIHTA) Mental health screening of adults in primary care
2024 Gesundheit Osterreich GmbH (GOeG) [Fecal immunochemical tests in comparison: umbrella review]
2024 Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection: a health technology assessment
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: type 2 diabetes screening and cardiovascular risk assessment]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding newborn screening for congenital adrenal hyperplasia to the Quebec newborn blood screening program]
2024 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Decision support software in ultrasound diagnosis for the classification of breast nodules]
2024 NIHR Health Services and Delivery Research programme Health screening clinic to reduce absenteeism and presenteeism among NHS Staff: eTHOS a pilot RCT
2024 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism by MS/MS. Update and assessment regional programs. Methylmalonic acidemias; Propionic acidaemia]
2024 Center for Drug Evaluation (CDE) [HTA Full report-Cost-effectiveness analysis of Pap smear screening and HPV testing]
2024 Center for Drug Evaluation (CDE) [HTA Full report-Cost-effectiveness analysis of adjusting the age and frequency of mammography subsidies]
2024 Basque Office for Health Technology Assessment (OSTEBA) [Use of self-sampling for the detection of human papillomavirus in cervical cancer screening]
2024 Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C: a short report update
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of vitamin B12 deficiency and other target diseases (homocystinuria, propionic acidaemia and methylmalonic acidaemia) in extended newborn screening (ENS)]
2024 HTA South [Artificial intelligence in breast cancer screening with mammography]
2023 Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for sickle cell disease
2023 Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for sickle cell disease and beta thalassaemia
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, efficacy, and economic evaluation of the implementation of an abdominal aortic aneurysm screening program]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023 NIHR Health Technology Assessment programme Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2023 Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness and safety of newborn screening for spinal muscular atrophy. Systematic review]
2023 Health Information and Quality Authority (HIQA) Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023 Malaysian Health Technology Assessment (MaHTAS) Ultra-portable digital x-ray system for TB screening
2023 NIHR Health Technology Assessment programme Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding the HbS/E, HbE/E and HbE/β-thal variants to the primary targets of the neonatal screening test for hemoglobinopathies]
2023 NIHR Health Technology Assessment programme Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023 National Institute for Health and Care Excellence (NICE) Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. NICE diagnostics guidance 56
2023 NIHR Health Technology Assessment programme Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023 Canary Health Service [Evaluation of the lung cancer screening program]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2023 Canary Health Service [Cost-effectiveness of newborn screening for tyrosinemia type I (update)]
2023 Ontario Health Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts
2023 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cost-utility analysis of universal neonatal screening for critical congenital heart disease based on pulsioximetry in Spain]
2023 Health Information and Quality Authority (HIQA) Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023 Health Information and Quality Authority (HIQA) Health technology assessment of the addition of spinal muscular atrophy (SMA) to the National Newborn Bloodspot Screening Programme
2023 Canary Health Service [Clinical effectiveness and cost-effectiveness of the extension of colorectal cancer screening up to 74 years of age in general population]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevant practices for promoting hearing health in long-term residential care settings]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: measurement and monitoring of total serum bilirubin in a newborn with signs suggestive of neonatal jaundice]
2023 National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment. NICE HealthTech guidance 696
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blood values: do older people benefit from regular determination of vitamin B12 and vitamin D levels in the blood?]
2022 Austrian Institute for Health Technology Assessment (AIHTA) [Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme]